SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Says GlaxoSmithKline Drug Promacta Fails to Control Bleeding

May 29, 2008 | 
1 min read
WASHINGTON - An experimental drug from GlaxoSmithKline does not significantly lower bleeding in patients with a rare blood disorder, according to the Food and Drug Administration.
Regulatory
GlaxoSmithKline Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Minimal Clip Art Collage. Pop Vector Design Composition with bright bold geometric shapes, halftone objects for ad, animation etc
Approvals
First Commissioner’s Priority Review Approval Goes to Decades-Old Antibiotic
December 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
December 10, 2025
 · 
1 min read
 · 
Heather McKenzie
Two businessmen negotiating with big speech bubbles
Rare diseases
Saol To Pitch Ultrarare Disease Drug as “Poster Child” for RDEP Program
December 9, 2025
 · 
2 min read
 · 
Heather McKenzie
FDA signage at its headquarters in Maryland
FDA
CAR-T Developers Will Need Randomized Trials as FDA Eyes Tighter Approval Requirements
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac